ConductScience.org, home

Comparison · NCT04976777-77c54fff

Updated DEX PS DDS 0.7 mg vs Approved DEX PS DDS 0.7 mg: Number of Participants Experiencing at Least One Adverse Events (AEs)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Updated DEX PS DDS 0.7 mg vs Approved DEX PS DDS 0.7 mg: Number of Participants Experiencing at Least One Adverse Events (AEs). Trial comparisons, record NCT04976777-77c54fff. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04976777-77c54fff

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.3610.2250.524wilson
Risk in group 20.3890.2030.614wilson
Risk difference, group 1 minus group 2-0.0278-0.2910.22newcombe hybrid score
Risk ratio, group 1 over group 20.9290.451.92log
Odds ratio, group 1 over group 20.8880.2772.85log
Number needed to treat, for one fewer participant with the outcome on Updated DEX PS DDS 0.7 mg than on Approved DEX PS DDS 0.7 mg36from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Updated DEX PS DDS 0.7 mgDEX PS DDS 0.7 mg implant was administered intravitreally into the study eye using updated applicator at Day 1 and followed until Day 7.1336OG000
Group 2Approved DEX PS DDS 0.7 mgDEX PS DDS 0.7 mg implant was administered into the study eye using currently approved applicator at Day 1 and followed until Day 7.718OG001

Outcome

Type
PRIMARY
Title
Number of Participants Experiencing at Least One Adverse Events (AEs)
Description
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
Time frame
Up to 7 Days After Study Drug Administration
Population
SAS included of all participants who received DEX PS DDS Implant.

Source ClinicalTrials.gov

Trial

Title
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
NCT number
NCT04976777
Phases
PHASE3
Conditions
Macular Edema
Interventions
Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone
Lead sponsor
AbbVie
Results first posted
2023-02-28

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04976777-77c54fff